SCM
CTMX icon

Silverarc Capital Management’s CytomX Therapeutics CTMX Stock Holding History

Silverarc Capital Management’s Portfolio CTMX Stock Details CTMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-385,974
Closed -$1.64M – 76
2025
Q4 		$1.64M Buy
+385,974
New +$1.47M 0.23% 59

Other funds holding CTMX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Silverarc Capital Management's CTMX Position: Q1 2026 in Review

Silverarc Capital Management sold out of CytomX Therapeutics (CTMX) in Q1 2026, closing a stake of 385,974 shares — an estimated $1.64M sold.

Silverarc Capital Management first reported a position in CTMX in Q4 2025 and held it in 1 quarter. The position peaked at $1.64M in Q4 2025. 179 funds tracked by Wall St. Rank hold CTMX as of Q1 2026.

  • Silverarc Capital Management reported no remaining CytomX Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Silverarc Capital Management sold 385,974 CytomX Therapeutics shares in Q1 2026, an estimated $1.64M.
  • Silverarc Capital Management first reported a position in CytomX Therapeutics in Q4 2025 and held it in 1 quarter.
  • Silverarc Capital Management's CytomX Therapeutics position peaked at $1.64M in Q4 2025.
  • 179 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q1 2026.

Based on Silverarc Capital Management's 13F filing for Q1 2026, filed 14 May 2026.